STUDY OF THE EXPRESSION OF CIRCULATING AND INTRA-TUMORAL CHEMOKINES IN PATIENTS WITH PROSTATE CANCER

Study Overview
=================
Brief Summary
-----------------
Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)

Detailed Description
-----------------
This project is an exploratory study, based on the hypothesis of involvement of chemokines in hormonal escape of prostate cancers. The two main objectives are: To describe the variations in expression of chemokines in serum and urine level in patients with prostate cancer And to study the disease stage and intra-prostatic concentrations of chemokines based on serum and urine concentrations of chemokines before treatment initiation. These estimates can be used in future trials set up for the management of prostate cancer

Official Title
-----------------
TUDY OF THE EXPRESSION OF CIRCULATING AND INTRA-TUMORAL

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Other: Blood samples
* Other: Urine samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant) Patients with a detectable PSA (Prostate-Specific Antigen) Patients who signed an informed consent Patients over 18 years Patients belonging to the social security scheme Exclusion Criteria: Active Hepatitis B or C virus HIV positive Patients who have received prior chemotherapy Patients with a second neoplasia treated in the last 5 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prospective cohort<br>Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology. | Other: Blood samples<br>* Additional blood samples at baseline, 6, 12, 18 and 24 months.<br>Other: Urine samples<br>* Additional urine samples at baseline, 6, 12, 18 and 24 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At baseline | 
| Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At 6 months | 
| Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At 12 months | 
| Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At 18 months | 
| Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At 24 months | 
| Blood urine and prostatic concentration of chemokines at baseline: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical |  | At baseline |